id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S3905 R8274 |
Schaffer (Controls unexposed, NOS), 2019 | Gestational hypertension | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) excluded | Adjustment: No |
1.73 [1.39;2.15] C excluded (control group) |
93/878 8,668/135,252 | 8,761 | 878 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3907 R8283 |
Schaffer (Controls unexposed, sick), 2019 | Gestational hypertension | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: No | 1.65 [1.21;2.24] C | 93/878 85/1,266 | 178 | 878 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2336 R2739 |
Petersen (Control discontinued treatment before pregnancy), 2016 | Preeclampsia | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: No | 0.92 [0.42;2.03] C | 12/280 14/302 | 26 | 280 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3847 R8170 |
Petersen (Control exposed to FGA), 2016 | Preeclampsia | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
2.30 [0.64;8.27] C excluded (control group) |
12/280 3/157 | 15 | 280 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2398 R3007 |
Petersen (Control unexposed, disease free), 2016 | Preeclampsia | 1st trimester | retrospective cohort (claims database) | unexposed, disease free excluded | Adjustment: No |
1.48 [0.83;2.64] C excluded (control group) |
12/280 9,355/318,434 | 9,367 | 280 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2329 R2699 |
Bellet - Aripiprazole, 2015 | Preeclampsia / eclampsia | 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No | 0.66 [0.07;6.47] | 1/86 3/172 | 4 | 86 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2294 R3112 |
Vigod, 2015 | Hypertensive disorders of pregnancy | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Matched | 1.12 [0.70;1.78] | 43/923 42/1,021 | 85 | 923 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2334 R8124 |
Hironaka (Control unexposed, disease free), 2011 | Pregnancy induced hypertension | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, disease free excluded | Adjustment: No |
6.48 [0.29;145.66] C excluded (control group) |
0/9 2/278 | 2 | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S14447 R57312 |
Hironaka (Control unexposed, sick), 2011 | Pregnancy induced hypertension | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No | 0.29 [0.00;18.96] C | 0/9 0/3 | 0 | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 5 studies | 1.38 [1.08;1.76] | 293 | 2,176 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Controls unexposed, sick; 2: Control discontinued treatment before pregnancy; 3: Control unexposed, sick;
Asymetry test p-value = 0.1089 (by Egger's regression)
slope=0.5808 (0.1431); intercept=-1.1696 (0.5174); t=2.2606; p=0.1089
excluded 2334, 3847, 2398, 3905